Related Experiment Video
Updated: Aug 5, 2026
Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress
Published on: August 31, 2015
Myeloperoxidase (MPO) inhibitors: an updated patent review (2020 - present)
Zhiwei Meng1, Dan Chen1, Xingyu Yao1
1Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei, China.
Introduction:
Myeloperoxidase (MPO), a key enzyme involved in neutrophil extracellular trap formation and other inflammatory processes, has emerged as an attractive therapeutic target for cardiovascular, central nervous system, respiratory, and autoimmune diseases. To date, four irreversible MPO inhibitors have entered clinical trials; however, none have reached the market, highlighting the challenges of MPO drug discovery.
Areas Covered:
This review provides an overview of MPO biology, its pathological roles in inflammatory diseases, and recent advances in MPO drug discovery. It then systematically summarizes patent literature published between 2020 and 2026, identified through Espacenet, Google Patents, and SciFinder, comprehensively covering the structural optimization and pharmacological characterization of emerging MPO inhibitors, including small molecules, peptides, and antibodies.
Expert Opinion:
Patent analysis indicates that MPO drug discovery remains heavily dependent on legacy thioxanthine/deazathioxanthine scaffolds. Current efforts are primarily focused on overcoming historical liabilities through improving target selectivity and pharmacokinetic properties. In parallel, non-thioxanthine chemotypes are emerging, although most still exhibit suboptimal potency and therefore require further optimization. The development of dual- or multi-target MPO inhibitors may represent a promising strategy for addressing complex inflammatory networks.
Insights
Myeloperoxidase (MPO) inhibitors show promise for inflammatory diseases, but drug discovery faces challenges. Recent patents reveal efforts to improve existing scaffolds and explore new chemical types for better MPO-targeted therapies.
Area of Science:
- Biochemistry
- Pharmacology
- Medicinal Chemistry
Background:
- Myeloperoxidase (MPO) is a key enzyme in inflammation and a therapeutic target for various diseases.
- Despite clinical trials, no MPO inhibitors have reached the market, indicating significant drug discovery hurdles.
Purpose of the Study:
- To review MPO biology, its role in diseases, and recent MPO inhibitor advancements.
- To systematically analyze patent literature from 2020-2026 on MPO inhibitor structural optimization and pharmacology.
Main Methods:
- Systematic review of patent literature from Espacenet, Google Patents, and SciFinder.
- Analysis of structural optimization and pharmacological characterization of MPO inhibitors.
- Categorization of inhibitors into small molecules, peptides, and antibodies.
Main Results:
- MPO drug discovery heavily relies on thioxanthine/deazathioxanthine scaffolds, with current focus on improving selectivity and pharmacokinetics.
- Emerging non-thioxanthine chemotypes show potential but require further optimization for potency.
- Dual- or multi-target MPO inhibitors are a promising strategy for complex inflammatory conditions.
Conclusions:
- Continued innovation in MPO inhibitor scaffolds and design is crucial for therapeutic success.
- Addressing limitations of existing MPO inhibitors is key to advancing treatments for inflammatory diseases.
- Exploring novel strategies like multi-targeting may overcome challenges in MPO-based drug discovery.
Related Concept Videos
01:21Antiprotozoal Agents
01:25Clinical Significance of Antibiotic Resistance
01:24Peroxisomes
01:26FDA Approved Drugs: Changes to Approved Drugs
01:26Pharmaceutical Poisoning: Treatment Strategies
01:25Mechanism of Antibiotic Resistance in MRSA